Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Personalized Medicine Versus The Public Health: FDA Debates The “Polypill”

This article was originally published in RPM Report

Executive Summary

FDA is beginning to solicit input from the medical community on review issues for a multi-ingredient cardiovascular product designed to control hypertension, platelet aggregation and cholesterol levels. The key issue is whether convenience and broad access make up for loss of individualized dosing. That is an important debate in the era of personalized medicine.

You may also be interested in...



Margaret Hamburg: The Public Health Commissioner

An interview with newly confirmed FDA Commissioner Margaret Hamburg.

A New Start: President Biden Visits Pfizer

President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.

COVID Therapeutics Progress (Or Lack Thereof) May Be Political Vulnerability For US FDA

COVID treatments have not advanced as rapidly or as publicly as vaccines. That may trigger some issues for the US FDA as Congress digs into the next phase of the COVID response – and starts to assess agency performance and leadership after the crisis.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel